An investigation for investors in NASDAQ:CHMA shares over potential securities laws violations by Chiasma in connection certain financial statements was announced.
Investors who purchased shares of Chiasma Inc (NASDAQ:CHMA), have certain options and should contact the Shareholders Foundation at email@example.com or call +1(858) 779 – 1554.
The investigation by a law firm focuses on whether a series of statements by Chiasma regarding its business, its prospects and its operations were materially false and misleading at the time they were made.
On April 15, 2016, U.S. Food and Drug Administration (“FDA”) reported its decision on Chiasma’s acromegaly candidate, Mycappsa. The FDA issued a complete response letter and said that the new drug application (NDA) for its treatment of a rare ailment related to the pituitary gland was not ready for approval in its present form. Shares of Chiasma Inc (NASDAQ:CHMA) closed on May 3, 2016 at $3.13 per share.
Those who purchased NASDAQ:CHMA shares have certain options and should contact the Shareholders Foundation.
Shareholders Foundation, Inc.
3111 Camino Del Rio North – Suite 423
92108 San Diego